Mdm2: A regulator of cell growth and death

Advances in Cancer Research

Volumn 89, Issue , 2003, Pages 1-34

  Vargas, Dania Alarcon ^a   Takahashi, Shoichi ^a   Ronai, Ze'ev ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; MDM2 PROTEIN, HUMAN; MESSENGER RNA; NUCLEAR PROTEIN; ONCOPROTEIN; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; CANCER; CELL DEATH; CELL GROWTH; CELL TRANSFORMATION; ENZYME ACTIVITY; GENE CONTROL; GENE FUNCTION; GENE INTERACTION; GENE STRUCTURE; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; RNA SPLICING; TUMOR CELL; TUMOR SUPPRESSOR GENE; ALTERNATIVE RNA SPLICING; ANIMAL; CELL DIVISION; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

ALTERNATIVE SPLICING; ANIMALS; CELL DEATH; CELL DIVISION; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 0642368221     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(03)01001-7     Document Type: Article

References (202)

1. Actor, B., Cobbers, J. M., Buschges, R., Wolter, M., Knobbe, C. B., Reifenberger, G., and Weber, R. G. (2002). Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosomes Cancer 34, 416-427.
2. Adler, V., Pincus, M. R., Minamoto, T., Fuchs, S. Y., Bluth, M. J., Brandt-Rauf, P. W., Friedman, F. K., Robinson, R. C., Chen, J. M., Wang, X. W., Harris, C. C., and Ronai, Z. (1997). Conformation-dependent phosphorylation of p53. Proc. Natl. Acad. Sci. USA 94, 1686-1691.
3. Alarcon-Vargas, D., and Ronai, Z. (2002). p53-Mdm2: The affair that never ends. Carcinogenesis 23, 541-547.
4. Appella, E., and Anderson, C. W. (2001). Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268, 2764-2772.
5. Ard, P. G., Chatterjee, C., Kunjibettu, S., Adside, L. R., Gralinski, L. E., and McMahon, S. B. (2002). Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes. Mol. Cell. Biol. 22, 5650-5661.
6. Arribas, B., Cristobal, E., Alcazar, J. A., Tardio, J., Matinez-Montero, J. C., Polo, J. R., Carrion, R., Gil, L., Azanedo, M., Rojas, J. M., and Menarguez, J. (2002). p53/MDM2 pathway aberrations in parathyroid tumors: p21 (WAF-1) and MDM2 are frequently overexpressed in parathyroid adenomas. Genes Chromosomes Cancer 34, 416-427.
7. Babst, M., Odorizzi, G., Estepa, E. J., and Emr, S. D. (2000). Mammalian tumor susceptibility gene 101 (TSG101) and the yeast homologue, Vps23p, both function in late endosomal trafficking. Traffic 1, 248-258.
8. Balint, E., Bates, S., and Vousden, K. H. (1999). Mdm2 binds p73α without targeting degradation. Oncogene 18, 3923-3929.
9. Baptiste, N., Friedlander, P., Chen, X., and Prives, C. (2002). The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 21, 9-21.
10. Bargonetti, J., and Manfredi, J. J. (2002). Multiple roles of the tumor suppressor p53. Curr. Opin. Oncol. 14, 86-91.
11. Barlev, N. A., Liu, L., Chehab, N. H., Mansfieild, K., Harris, K. G., Halazonetis, T. D., and Berger, S. L. (2001). Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8, 1243-1254.
12. Bartel, F., Taubert, H., and Harris, L. C. (2002). Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2, 9-15.
13. Baskaran, R., Wood, L. D., Whitaker, L. L., Canman, C. E., Morgan, S. E., Xu, Y., Barlow, C., Baltimore, D., Wynshaw-Boris, A., Kastan, M. B., and Wang, J. Y. (1997). Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387, 450-451.
14. Bates, S., Phillips, A. C., Clark, P. A., Stott, E, Peters, G., Ludwig, R. L., and Vousden, K. H. (1998). p14ARF links the tumor suppressors RB and p53. Nature 395, 124-125.
15. Benchimol, S., Lamb, P., Crawford, L. V., Sheer, D., Shows, T. B., Bruns, G. A. P., and Peacock, J. (1985). Transformation associated p53 protein is encoded by a gene on human chromosome 17. Somat. Cell Mol. Genet. 11, 505-509.
16. Blattner, C., Hay, T., Meek, D. W., and Lane, D. P. (2002). Hypophosphorylation of Mdm2 augments p53 stability. Mol. Cell. Biol. 22, 6170-6182.
17. Blaydes, J. P., Gire, V., Rowson, J. M., and Wynford-Thomas, D. (1997). Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2. Oncogene 14, 1859-1868.
18. Boddy, M. N., Freemont, P. S., and Borden, K. L. (1994). The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends Biochem. Sci. 19, 198-199.
19. Bottger, A., Bottger, V., Sparks, A., Liu, W.-L., Howard, S. F., and Lane, D. P. (1997). Design of synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7, 860-869.
20. 1 arrest that is suppressed by MDM2. J. Biol. Chem. 275, 31883-31890.
21. Brown, D. R., Thomas, C. A., and Deb, S. P. (1998). The human oncoprotein MDM2 arrests the cell cycle: Elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J. 17, 2513-2525.
22. Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., and Hannon, G. J. (1995). Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377, 552-557.
23. Bueso-Ramos, C. E., Manshouri, T., Haidar, M. A., Yang, Y., McCrown, P., Ordonez, N., Glassman, A., Sneige, N., and Albitar, M. (1996). Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res. Treat. 37, 179-188.
24. ARF, and p300/CBP during the cell cycle and after exposure to ultraviolet irradiation. Can. Res. 60, 896-900.
25. Buschmann, T., Lerner, D., Lee, C.-G., and Ronai, Z. (2001a). The Mdm-2 amino terminus is required for Mdm2 binding and SUMO-1 conjugation by the E2 Sumo-1 conjugation enzyme Ubc9. J. Biol. Chem. 276, 40389-40395.
26. 1131. J. Biol. Chem. 276, 13852-13857.
27. 2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities. Mol. Cell. Biol. 21, 2743-2754.
28. Cahilly-Snyder, L., Yang-Feng, T., Francke, U., and George, D. L. (1987). Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. 13, 235-244.
29. Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., and Siliciano, J. D. (1998). Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281, 1677-1679.
30. Chang, D., Chen, F., Zhang, F., McKay, B. C., and Ljungman, M. (1999). Dose-dependent effects of DNA-damaging agents on p53-mediated cell cycle arrest. Cell Growth Differ. 10, 155-162.
31. Chang, Y.-C., Lee, Y.-S., Tejima, T., Tanaka, K., Omura, S., Heintz, N. H., Mitsui, Y., and Magae, J. (1998). mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 9, 79-84.
32. Chao, C., Saito, S., Kang, J., Anderson, C. W., Appella, E., and Xu, Y. (2000). p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J. 19, 4967-4975.
33. Chene, P., Fuchs, J., Bohn, J., Garcia-Echeverria, C., Furet, P., and Fabbro, D. (2000). A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumor cell lines. J. Mol. Biol. 299, 245-253.
34. Cho, Y., Gorina, S., Jeffrey, P.D., and Pavletich, N. P. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265, 346-355.
35. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F., and Levine, A. J. (1994). Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54, 794-799.
36. Dang, C. V., and Lee, W. M. F. (1999). Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins. J. Biol. Chem. 264, 18019-18023.
37. Dang, J., Kuo, M.-L., Eischen, C. M., Stepanova, L., Sherr, C. J., and Roussel, M. F. (2002). The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res. 62, 1222-1230.
38. Daujat, S., Neel, H., and Piette, J. (2001). MDM2: Life without p53. Trends Genet. 17, 459-464.
39. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-684.
40. Deng, Y., and Wu, X. (2000). Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc. Natl. Acad. Sci. USA 97, 12050-12055.
41. Di Como, C. J., Gaiddon, C., and Prives, C. (1999). p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19, 1438-1449.
42. Dobbelstein, M., and Roth, J. (1998). The large T antigen of simian virus 40 binds and inactivates p53 but not p73. J. Gen. Virol. 79, 3079-3083.
43. Dobbelstein, M., Wienzek, S., Konig, C., and Roth, J. (1999). Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 18, 2101-2106.
44. Dubs-Poterszman, M. C., Tocque, B., and Wasylyk, B. (1995). MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene 11, 2445-2449.
45. Dulic, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Less, E., Harper, J. W., Elledge, S. J., and Reed, S. I. (1994). p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76, 1013-1023.
46. El-Deiry, W. S., Tokin, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
47. Elenbaas, B., Dobbelstein, M., Roth, J., Shenk, T., and Levine, A. J. (1996). The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med. 2, 439-451.
48. Espinosa, J. M., and Emerson, B. M. (2001). Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8, 57-69.
49. Evans, S. C., Viswanathan, M., Grier, J. D., Narayana, M., El-Naggar, A. K., and Lozano, G. (2001). An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogens 20, 4041-4049.
50. Evdokiou, A., Atkins, G. J., Bouralexis, S., Hay, S., Raggatt, L. J., Cowled, P. A., Graves, S. E., Clayer, M., and Findlay, D. M. (2001). Expression of alternatively-spliced MDM2 transcripts in giant cell tumours of bone. Int. J. Oncol. 19, 625-632.
51. Fakharzadeh, S. S., Trusko, S. P., and George, D. L. (1991). Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10, 1656-1659.
52. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., and Weissman, A. M. (2000). Mdm2 Is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945-8951.
53. Ferbeyre, G., de Stanchina, E., Querido, E., Baptiste, N., Prives, C., and Lowe, S. W. (2000). PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 14, 2015-2027.
54. Finch, R. A., Donoviel, D. B., Potter, D., Shi, M., Fan, A., Freed, D. D., Wang, C.-Y., Zambrowicz, B. P., Ramirez-Solis, R., Sands, A. T., and Zhang, N. (2002). MdmX is a negative regulator of p53 activity in vivo. Cancer Res. 62, 3221-3225.
55. Fogal, V., Gostissa, M., Sandy, P., Zacchi, P., Sternsdorf, T., Jensen, K., Pandolfi, P. P., Will, H., Schneider, C., and Del Sal, G. (2000). Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J. 19, 6185-6195.
56. Fuchs, S. Y., Adler, V., Buschmann, T., Wu, X., and Ronai, Z. (1998a). Mdm2 association with p53 targets its ubiquitination. Oncogene 17, 2543-2547.
57. Fuchs, S. Y., Adler, V., Buschmann, T., Yin, Z., Wu, X., Jones, S. J., and Ronai, Z. (1998b). JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 12, 2658-2663.
58. Fuchs, S., Adler, V., Pincus, M. R., and Ronai, Z. (1998c). MEKK1/JNK signaling stabilizes and activates p53. Proc. Natl. Acad. Sci. USA 95, 10541-10546.
59. Goldberg, Z., Sionov, R. V., Berger, M., Zwang, Y., Perets, R., Van Etten, R. A., Oren, M., Taya, Y., and Haupt, Y. (2002). Tyrosine phosphorylation of Mdm2 by c-Abl: Implications for p53 regulation. EMBO J. 21, 3715-3727.
60. Gorina, S., and Pavletich, N. P. (1996). Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274, 1001-1005.
61. Gostissa, M., Hengstermann, A., Fogal, V., Sandy, P., Schwarz, S. E., Scheffner, M., and Del Sal, G. (1999). Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 18, 6462-6471.
62. Gottifredi, V., Shieh, S.-Y., Taya, Y., and Prives, C. (2001). p53 accumulates but is functionally impaired when DNA synthesis is blocked. Proc. Natl. Acad. Sci. USA 98, 1036-1041.
63. Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z.-X., Kumar, S., Howley, P. M., and Livingston, D. M. (1998). p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell 2, 405-415.
64. Gu, J., Chen, D., Rosenblum, J., Rubin, R. M., and Yuan, Z.-M. (2000). Identification of a sequence element from p53 that signals for Mdm2-targeted degradation. mol. Cell. Biol. 20, 1243-1253.
65. Gu, J., Kawai, H., Nie, L., Kitao, H., Wiederschain, D., Jochemsen, A. G., Parant, J., Lozano, G., and Yuan, Z.-M. (2002). Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem. 277, 19251-19254.
66. Gu, W., and Roeder, R. G. (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 9, 595-596.
67. Guddat, U., Bakken, A. H., and Pieler, T. (1990). Protein-mediated nuclear export of RNA: 5S rRNA containing small RNPs in Xenopus oocytes. Cell 60, 619-628.
68. Guo, A., Salomoni, P., Luo, J., Shih, A., Zhong, S., Gu, W., and Pandolfi, P. P. (2000). The function of PML in p53-dependent apoptosis. Nature Cell Biol. 2, 730-736.
69. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816.
70. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
71. Hay, T. J., and Meek, D. W. (2000). Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. FEBS Lett. 478, 183-186.
72. Hochstrasser, M. (2000). Biochemistry: All in the ubiquitin family. Science 289, 563-564.
73. Hockenberry, D., Nunez, G., Milliman, C, Schreiber, R. D., and Korsmeyer, S. J. (1990). Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348, 334-336.
74. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18, 22-27.
75. Hsieh, J.-K., Chan, F. S. G., O'Connor, D. J., Mittnacht, S., Zhong, S., and Lu, X. (1999). RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell 3, 181-193.
76. Inoue, T., Geyer, R. K., Howard, D., Yu, Z. K., and Maki, C. G. (2001). MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J. Biol. Chem. 276, 45255-45260.
77. Isobe, M., Emanuel, B. S., Givol, D., Oren, M., and Croce, C. M. (1986). Localization of gene for human p53 tumour antigen to band 17p13. Nature 320, 84-85.
78. Ito, A., Lai, C.-H., Zhao, X., Saito, S., Hamilton, M. H., Appella, E., and Yao, T.-P. (2001). p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20, 1131-1340.
79. Iwabuchi, K., Bartel, P. L., Li, B., Marraccino, R., and Fields, S. (1994). Two cellular proteins that bind to wild-type but not mutant p53. Proc. Natl. Acad. Sci. USA 91, 6098-6102.
80. Jackson, M. W., and Berberich, S. J. (2000). MdmX protects p53 from Mdm2-mediated degradation. Mol. Cell. Biol. 20, 1001-1007.
81. Jimenez, G. S., Nister, M., Stommel, J. M., Beeche, M., Barcarse, E. A., Zhang, X.-Q., O'Gorman, S., and Wahl, G. M. (2000). A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nature Genet. 26, 37-43.
82. Johnson-Pais, T., Degnin, C., and Thayer, M. J. (2001). pRB induces Sp1 activity by relieving inhibition mediated by MDM2. Proc. Natl. Acad. Sci. USA 98, 2211-2216.
83. Jones, S. N., Hancock, A. R., Vogel, H., Donehower, L. A., and Bradley, A. (1998). Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA 95, 15608-15612.
84. Jones, S. N., Roe, A. E., Donehower, L. A., and Bradley, A. (1995). Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378, 206-208.
85. Jost, C. A., Marin, M. C., and Kaelin, W. G., Jr. (1997). p73 is a human p53-related protein that can induce apoptosis. Nature 389, 191-194.
86. Juven-Gershon, T., Shifman, O., Unger, T., Elkeles, A., Haupt, Y., and Oren, M. (1998). The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol. Cell. Biol. 18, 3974-3982.
87. Kadakia, M., Slader, C., and Berberich, S. J. (2001). Regulation of p63 function by Mdm2 and MdmX. DNA Cell Biol. 20, 321-330.
88. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.-C., Valent, A., Minty, A., Chalon, P., Lelias, J.-M., Dumont, X., Ferrara, P., McKeon, F., and Caput, D. (1997). Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819.
89. Kamijo, T., Bodner, S., van de Kamp, E., Randle, D. H., and Sherr, C. J. (1999). Tumor spectrum in ARF-deficient mice. Cancer Res. 59, 2217-2222.
90. ARF. Cell 91, 649-659.
91. Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shiloh, Y., and Shkedy, D. (1999). Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc. Natl. Acad. Sci. USA 96, 14973-14977.
92. Ko, L. J., and Prives, C. (1996). p53: Puzzle and paradigm. Genes Dev. 10, 1054-1072.
93. Kobet, E., Zeng, X., Zhu, Y., Keller, D., and Lu, H. (2000). MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. USA 97, 12547-12552.
94. Koonin, E. V., and Abagyan, R. A. (1997). TSG101 may be the prototype of a class of dominant negative ubiquitin regulators. Nature Genet. 16, 330-331.
95. Kubbutat, M. H. G., Jones, S. N., and Vousden, K. H. (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303.
96. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., and Pavletich, N. P. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953.
97. Kwek, S. S. S., Derry, J., Tyner, A. L., Shen, Z., and Gudkov, A. V. (2001). Functional analysis and intracellular localization of p53 modified by SUMO-1. Oncogene 20, 2587-2599.
98. Leach, F. S., Tokino, T., Meltzer, P., Burrell, M., Oliner, J. D., Smith, S., Hill, D. E., Sidransky, D., Kinzler, K. W., and Vogelstein, B. (1993). p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53, 2231-2234.
99. Leng, P., Brown, D. R., Deb, S., and Deb, S. P. (1995). Human oncoprotein MDM2 interacts with the TATA-binding protein in vitro and in vivo. Int. J. Oncol. 6, 251-259.
100. II250 and is required for MDM2 regulation of the cyclin A promoter. J. Biol. Chem. 272, 30651-30661.
101. Levine, A. J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
102. Li, X., and Coffino, P. (1996). High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J. Virol. 70, 4509-4516.
103. Li, L., Liao, J., Ruland, J., Mak, T. W., and Cohen, S. N. (2001). ATSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. Proc. Natl. Acad. Sci. USA 98, 1619-1624.
104. Lin, H.-K., Wang, L., Hu, Y.-C., Altuwaijri, S., and Chang, C. (2002). Phosphorylation-dependent ubiquitination and degradation of androgen receptor by Akt require Mdm2 ligase. EMBO J. 21, 4037-4048.
105. Liu, L., Scolnick, D. M., Trievel, R. C., Zhang, H. B., Marmorstein, R., Halazonetis, T. D., and Berger, S. L. (1999). p53 sites ace in vitro by PCAF and P300 vivo in response to DNA. Cell Biol. 19, 1202-1209.
106. Loughran, O., and La Thangue, N. B. (2000). Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol. Cell. Biol. 20, 2186-2197.
107. II31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. USA 92, 5154-5158.
108. Lukas, J., Gao, D.-Q., Keshmeshian, M., Wen, W.-H., Tsao-Wei, D., Rosenberg, S., and Press, M. F. (2001). Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res. 61, 3212-3219.
109. Marechal, V., Elenbaas, B., Piette, J., Nicolas, J. C., and Levine, A. J. (1994). The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol. Cell. Biol. 14, 7414-7420.
110. Marin, M. C., Jost, C. A., Irwin, M. S., DeCaprio, J. A., Caput, D., and Kaelin, W. G., Jr. (1998). Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol. Cell. Biol. 18, 6316-6324.
111. Martin, K., Trouche, D., Hagemeier, C., Sorensen, T. S., La Thangue, N. B., and Kouzarides, T. (1995). Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375, 691-694.
112. Maya, R., Balass, M., Kim, S.-T., Shkedy, D., Leal, J.-F. M., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shilof, Y., Kastan, M. B., Katzir, E., and Oren, M. (2001). ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage. Genes Dev. 15, 1067-1077.
113. Mayo, L. D., and Donner, D. B. (2001). A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA 98, 11598-11603.
114. Mayo, L. D., Turchi, J. J., and Berberich, S. J. (1997). Mdm-2 phosphorylation by DNA-dependent protein kinases prevents interaction with p53. Cancer Res. 57, 5013-5016.
115. McBride, O. W., Merry, D., and Givol, D. (1986). The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc. Natl. Acad. Sci. USA 83, 130-134.
116. Mendrysa, S. A., and Perry, M. E. (2000). The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress. Mol. Cell. Biol. 20, 2023-2030.
117. Michael, D., and Oren, M. (2002). The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12, 53-59.
118. Miller, C., Mohandas, T., Wolf, D., Prokocimer, M., Rotter, V., and Koeffler, H. P. (1986). Human p53 gene localized in short arm of chromosome 17. Nature 319, 783-784.
119. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. (1994). Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9, 1799-1805.
120. Miyashita, T., and Reed, J. C. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299.
121. Miyauchi, Y., Yogosawa, S., Honda, R., Nishida, T., and Yasuda, H. (2002). Sumoylation of Mdm2 by PIAS and RanBP2 enzymes. J. Biol. Chem. Oct 18 epub.
122. Momand, J., Jung, D., Wilczynski, S., and Niland, J. (1998). The MDM2 gene amplification database. Nucleic Acids Res. 26, 3453-3459.
123. Momand, J., and Zambetti, G. P. (1997). Mdm-2: "Big brother" of p53. J. Cell. Biochem. 64, 343-352.
124. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245.
125. Montes de Oca Luna, R., Tabor, A. D., Eberspaecher, H., Hulboy, D. L., Worth, L. L., Colman, M. S., Finlay, C. A., and Lozano, G. (1996). The organization and expression of the mdm2 gene. Genomics 33, 352-357.
126. Montes de Oca Luna, R., Wagner, D. S., and Lozano, G. (1995). Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206.
127. Muller, S., Berger, M., Lehembre, F., Seeler, J.-S., Haupt, Y., and Dejean, A. (2000). c-Jun and p53 activity is modulated by SUMO-1 modification. J. Biol. Chem. 275, 13321-1329.
128. Nakamura, S., Roth, J. A., and Mukhopadhyay, T. (2000). Multiple lysine mutatins in the C-terminal domain of p53 interfere with Mdm2-dependent protein degradation and ubiquitination. Mol. Cell Biol. 20, 9391-9398.
129. Okorokov, A. L., Ponchel, E, and Milner, J. (1997). Induced N- and C-terminal cleavage of p53: A core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53. EMBO J. 19, 6008-6017.
130. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., and Vogelstein, B. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358, 80-83.
131. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. (1993). Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860.
132. Ongkeko, W. M., Wang, X. Q., Siu, W. Y., Lau, A. W., Yamashita, K., Harris, A. L., Cox, L. S., and Poon, R. Y. (1999). MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr. Biol. 9, 829-832.
133. Oren, M., Damalas, A., Gottlieb, T., Michael, D., Taplick, J., Leaf, J. R., Maya, R., Moas, M., Seger, R., Taya, Y., and Ben-Ze'ev, A. (2002). Regulation of p53: Intricate loops and delicate balances. Biochem. Pharmacol. 64, 865-871.
134. Oren, M. (1985). The p53 cellular tumor antigen: Gene structure, expression, and protein properties. Biochem. Biophys. Acta. 823, 67-78.
135. Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M., and Ikawa, S. (1998). Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nature Med. 4, 839-843.
136. Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W.-W., Kruzel, E., and Radinsky, R. (1995). Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol. 15, 3032-3040.
137. Pande, P., Soni, S., Kaur, J., Agarwal, S., Mathur, M., Shukla, N. K., and Ralhan, R. (2002). Prognostic factors in betel and tobacco related oral cancer. Oral Oncol. 38, 491-499.
138. Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsem, A. G., and Lozano, G. (2001). Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genet. 29, 92-95.
139. Pearson, M., Carbone, R., Sebatiani, C., Cioce, M., Fagioli, M., Saito, S., Higashimoto, Y., Appella, E., Minucci, S., Pandolfi, P. P., and Pelicci, P. G. (2000). PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406, 207-210.
140. MDM2 to destabilize p53. J. Biol. Chem. 275, 5733-5738.
141. Pfeifer, G. P. (2000). p53 mutational spectra and the role of methylated CpG sequences. Mutat. Res. 450, 155-166.
142. Pinkas, J., Naber, S. P., Butel, J. S., Medina, D., and Jerry, D. J. (1999). Expression of MDM2 during mammary tumorigenesis. Int. J. Cancer 81, 292-298.
143. Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., and Vogelstein, B. (1997). A model for p53-induced apoptosis. Nature 389, 300-305.
144. Ponting, C. P., Cai, Y. D., and Bork, P. (1997). The breast cancer gene product TSG101: A regulator of ubiquitination? J. Mol. Med. 75, 467-469.
145. Rallapalli, R., Strachan, G., Cho, B., Mercer, W. E., and Hall, D. J. (1999). A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. J. Biol. Chem. 274, 8299-8308.
146. ARF. Cell 103, 321-330.
147. Rodriguez, M. S., Desterro, J. M. P., Lain, S., Midgley, C. A., Lane, D. P., and Hay, R. T. (1999). SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18, 6455-6461.
148. Rosse, T., Olivier, R., Monney, L., Rager, M., Conus, S., Fellay, I., Jansen, B., and Borneer, C. (1998). Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature 391, 496-499.
149. Roth, J., Dobbelstein, M., Freedman, D. A., Shenk, T., and Levine, A. J. (1998). Nucleocytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17, 554-564.
150. Ruland, J., Sirard, C., Elia, A., MacPherson, D., Wakeham, A., Li, L., de la Pompa, J. L., Cohen, S. N., and Mak, T. W. (2001). p53 accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101. Proc. Natl. Acad. Sci. USA 98, 1859-1864.
151. Ruppert, J. M., and Stillman, B. (1993). Analysis of a protein-binding domain of p53. Mol. Cell Biol. 13, 3811-3820.
152. Saito, K., Tsujitani, S., Oka, S., Ikeguchi, M., Maeta, M., and Kaibara, N. (2002). The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation. Ann. Surg. Oncol. 9, 450-456.
153. Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., and Appella, E. (1998). DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12, 2831-2841.
154. Scheffner, M., Huibregtse, J. M., Vierstra, R. D., and Howley, P. M. (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505.
155. Schmale, H., and Bamberger, C. (1997). A novel protein with strong homology to the tumor suppressor p53. Oncogene 15, 1363-1367.
156. Selvakumaran, M., Lin, H.-K., Miyashita, T., Wang, H. G., Krajewski, S., Reed, J. C., Hoffman, B., and Liebermann, D. (1994). Immediate early up-regulation of bax expression by p53 but not TGFβ1: A paradigm for distinct apoptotic pathways. Oncogene 9, 1791-1798.
157. Sengupta, S., and Wasylyk, B. (2001). Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. Genes Dev. 15, 2367-2380.
158. Shafman, T., Khanna, K. K., Keadr, P., Spring, K., Kozlov, S., Yen, T., Hobson, K., Gatei, M., Zhang, N., Watters, D., Egerton, M., Shiloh, Y., Kharbanda, S., Kufe, D., and Lavin, M. F. (1997). Interaction between ATM protein and c-Abl in response to DNA damage. Nature 29, 520-523.
159. Sharp, D. A., Kratowicz, S. A., Sank, M. J., and George, D. L. (1999). Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem. 274, 38189-38196.
160. Shaw, P., Freeman, J., Bovey, R., and Iggo, R. (1996). Regulation of specific DNA binding by p53: Evidence for a role for O-glycosylation and charged residues at the corboxy-terminus. Oncogene. 12, 921-930.
161. Shenoy, S. K., McDonald, P. H., Kohout, T. A., and Lefkowitz, R. J. (2001). Regulation of receptor fate by ubiquitination of activated β2-adrenergic receptor and β-arrestin. Science 294, 1307-1313.
162. Shieh, S.-Y., Ikeda, M., Taya, Y., and Prives, C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334.
163. Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven, van Oordt, W., Hateboer, G., van der Eb, A. J., and Jochemsen, A. G. (1996). MDMX: A novel p53-binding protein with some functional properties of MDM2. EMBO J. 15, 5349-5357.
164. Sigalas, I., Calvert, A. H., Anderson, J. J., Neal, D. E., and Lunec, J. (1996). Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer. Nature Med. 2, 912-917.
165. Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., and Alnemri, E. S. (1998). Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell 1, 949-957.
166. Stad, R., Little, N. A., Xirodimas, D. P., Frenk, R., van der Eb, A. J., Lane, D. P., Saville, M. K., and Jochemsen, A. G. (2001). Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. EMBO J. 2, 1029-1034.
167. Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., and Wahl, G. M. (1999). A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18, 1660-1672.
168. Storey, A., Thomas, M., Kalita, A., Harwood, C., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I. M., Matlashewski, G., and Banks, L. (1998). Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393, 229-234.
169. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001-5014.
170. Strachan, G. D., Rallapalli, R., Pucci, B., Lafond, T. P., and Hall, D. J. (2001). A transcriptionally inactive E2F-1 targets the MDM family of proteins for proteolytic degradation. J. Biol. Chem. 276, 45677-45685.
171. Sun, P., Dong, P., Dai, K., Hannon, G. J., and Beach, D. (1998).
172. Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., and Ohtsubo, M. (1999). MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 447, 5-9.
173. ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. USA 96, 6937-6941.
174. Tao, W., and Levine, A. J. (1999b). Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA 96, 3077-3080.
175. II60. Science 267, 100-104.
176. Trink, B., Okami, K., Wu, L., Sriuranpong, V., Jen, J., and Sidransky, D. (1998). A new human p53 homologue. Nature Med. 4, 747-748.
177. Urist, M., and Prives, C. (2002). p53 leans on its siblings. Cancer Cell 1, 311-313.
178. Vousden, K. H., and Lu, X. (2002). Live or let die: The cell's response to p53. Nature Rev. Cancer 2, 594-604.
179. Walker, K. K., and Levine, A. J. (1996). Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA 93, 15335-15340.
180. Wang, H., Zeng, X., Oliver, P., Le, L. P., Chen, L., Zhou, W., Agrawal, S., and Zhang, R. (1999). MDM2 oncogene as a target for cancer therapy: An antisense approach. Int. J. Oncol. 15, 653-660.
181. Wang, X. Q., Arooz, T., Siu, W. Y., Chiu, C. H. S., Lau, A., Yamashita, K., and Poon, R. Y. C. (2001). MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett. 490, 202-208.
182. Wang, X. Q., Ongkeko, W. M., Lau, A. W. S., Leung, K. M., and Poon, R. Y. C. (2001). A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res. 61, 1598-1603.
183. Wasylyk, C., Salvi, R., Argentini, M., Dureuil, C., Delumeau, I., Abecassis, J., Debussche, L., and Wasylyk, B. (1999). p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 18, 1921-1934.
184. Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., and Bar-Sagi, D. (1999). Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Bio. 1, 20-27.
185. Wu, G. S., Burns, T. F., McDonald, E. R., 3rd, Jiang, W., Meng, R., Krantz, I. D., Kao, G., Can, D. D., Zhou, J. Y., Muschel, R., Hamilton, S. R., Spinner, N. B., Markowitz, S., Wu, G., and el-Deiry, W. S. (1997). KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet. 17, 141-143.
186. Wulf, G. M., Liou, Y. C., Ryo, A., Lee, S. W., and Lu, K. P. (2002). Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J. Biol. Chem. Oct 17 epub.
187. Wurl, P., Meye, A., Schmidt, H., Lautenschlager, C., Kaltoff, H., Rath, F. W., and Taubert, H. (1998). High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 16, 1183-1185.
188. Xiao, Z. X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J., Sellers, W. R., and Livingston, D. M. (1995). Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375, 694-698.
189. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704.
190. Xirodimas, D., Chisholm, J., Detserro, J., Lane, D., and Hay, R. (2002). P14ARF promotes accumulation of SUMO-1 conjugated (H) Mdm2. FEBS Lett. 528, 1-3.
191. Yam, C. H., Siu, W. Y., Arooz, T., Chiu, C. H. S., Lau, Á., Wang, X. Q., and Poon, R. Y. C. (1999). MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins. Cancer Res. 59, 5075-5078.
192. Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dotsch, V., Andrews, N. C., Caput, D., and McKeon, F. (1998). p63, a p53 homolog at 3q27-29 encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2, 305-316.
193. Yew, P. R., Liu, X., and Berk, A. J. (1994). Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev. 8, 190-202.
194. Zacchi, P., Gostissa, M., Uchida, T., Salvagno, C., Avolio, F., Volinia, S., Ronai, Z., Blandino, G., Schneider, C., and Del Sal, G. (2002). The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419, 853-857.
195. Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Jr., Oren, M., Chen, J., and Lu, H. (1999). MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. 19, 3257-3266.
196. Zhang, T., and Prives, C. (2001). Cyclin A-CDK phosphorylation regulates MDM2 protein interactions. J. Biol. Chem. 176, 29702-29710.
197. Zhao, J., Wang, M., Chen, J., Luo, A., Wang, X., Wu, M., Yin, D., and Liu, Z. (2002). The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. 183, 69-77.
198. Zhao, R., Gish, K., Murphy, M., Notterman, D., Hoffman, W. H., Tom, E., Mack, D. H., and Levine, A. J. (2000). Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14, 981-993.
199. Zheng, H., You, H., Zhou, X. Z., Murray, S. A., Uchida, T, Wulf, G., Gu, L., Tang, X., Lu, X. P., and Xiao, Z. X. (2002). The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419, 849-853.
200. Zhou, B. P., and Hung, M. C. (2002). Novel targets of Akt, p21, and MDM2. Semin. Oncol. 29, 62-70.
201. Zhou, B. P., Liao, Y., Xia, W., Zhou, Y., Spohn, B., and Hung, M.-C. (2001). HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nature Cell Biol. 3, 973-982.
202. Zhu, J., Jiang, J., Zhou, W., and Chen, X. (1998). The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 58, 5061-5065.